Intravitreal Injection of Conbercept Combined with Dexamethasone for Macular Edema Following Central Retinal Vein Occlusion

References

• Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–9.e1. doi:10.1016/j.ophtha.2009.07.017
   PubMed Web of Science ®Google Scholar
• Miller JW, Le CJ, Strauss EC, Ferrara N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology. 2013;120(1):106–114. doi:10.1016/j.ophtha.2012.07.038
   PubMed Web of Science ®Google Scholar
• Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50(3):1025–1032. doi:10.1167/iovs.08-2510
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology. 2010;117(6):1102–1112.e1. doi:10.1016/j.ophtha.2010.02.021
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular oedema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–2049. doi:10.1016/j.ophtha.2011.02.038
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. Baseline factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular oedema secondary to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 Study Report 4. JAMA Ophthalmol. 2017;135:639–649. doi:10.1001/jamaophthalmol.2017.1141
   PubMed Web of Science ®Google Scholar
• Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood‐retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48. doi:10.1016/j.preteyeres.2013.02.001
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem. 2002;80:667–677. doi:10.1046/j.0022-3042.2001.00740.x
   PubMed Web of Science ®Google Scholar
• Eter N, Mohr A, Wachtlin J, et al. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):77–87. doi:10.1007/s00417-016-3431-x
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) study. Am J Ophthalmol. 2015;160(2):313–321.e19. doi:10.1016/j.ajo.2015.04.025
   PubMed Web of Science ®Google Scholar
• Hoerauf H, Feltgen N, Weiss C, et al. Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol. 2016;169:258–267. doi:10.1016/j.ajo.2016.04.020
   PubMed Web of Science ®Google Scholar
• Nghiem-Buffet S, Baillif S, Regnier S, Skelly A, Yu N, Sodi A. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye. 2017;31(4):551–559. doi:10.1038/eye.2016.269
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang Z, Yan M, Hong L, Yang C, Dechao Y. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis. 2008;14:37–49.
   PubMed Web of Science ®Google Scholar
• Zhang M, Dechao Y, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1):204–210. doi:10.1007/s11095-008-9718-9
   PubMed Web of Science ®Google Scholar
• Wang Q, Tao L, Zhigang W, et al. Novel VEGF decoy receptor fusion protein Conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One. 2013;8(8):e70544. doi:10.1371/journal.pone.0070544
   PubMed Web of Science ®Google Scholar
• Li X, Xu G, Wang Y, et al. Safety and efficacy of Conbercept in neovascular age-related macular degeneration. Results from a 12-month randomized Phase 2 study: aurora study. Ophthalmology. 2014;121(9):1740–1747. doi:10.1016/j.ophtha.2014.03.026
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhou H, Lin B, et al. Efficacy and safety of intravitreal Conbercept injections in macular edema secondary to retinal vein occlusion. Retina. 2017;37(9):1723–1730. doi:10.1097/MD.0000000000020222
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Chew EY, Jonghyeon K, Sperduto RD, et al. Evaluation of the age-related eye disease study clinical lens grading system. AREDS report no. 31. Ophthalmology. 2010;117(11):2112–9.e3. doi:10.1016/j.ophtha.2010.02.033
   PubMed Web of Science ®Google Scholar
• Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet‐activating factor and platelet‐derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997;16(4):398–406. doi:10.1165/ajrcmb.16.4.9115750
   PubMed Web of Science ®Google Scholar
• Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–1444. doi:10.1167/iovs.04-0905
   PubMed Web of Science ®Google Scholar
• Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002;120(9):1217–1219.
   PubMedGoogle Scholar
• Haller JA, Bandello F, R B Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.e3. doi:10.1016/j.ophtha.2010.03.032
   PubMed Web of Science ®Google Scholar
• Bezatis A, Spital G, Höhn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up–-The SOLO study. Acta Ophthalmol. 2013;91(5):e340–7. doi:10.1111/aos.12020
   PubMed Web of Science ®Google Scholar
• Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. The central vein occlusion study group. Arch Ophthalmol. 1997;115(10):1275. doi:10.1001/archopht.1997.01100150488006
   Google Scholar
• Sweta VD, Shibi Dev BN, Sandhya R. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: a retrospective study. Indian. J Ophthalmol. 2022;70(2):585–589. doi:10.4103/ijo.IJO_684_21
   Web of Science ®Google Scholar